Analysts See $2.09 EPS for Canadian Imperial Bank of Commerce (USA) (CM); Kura Oncology (KURA) Shorts Up By 36.6%

November 15, 2017 - By Ellis Scott

Analysts expect Canadian Imperial Bank of Commerce (USA) (NYSE:CM) to report $2.09 EPS on November, 30 before the open.They anticipate $0.11 EPS change or 5.56% from last quarter’s $1.98 EPS. CM’s profit would be $918.04M giving it 10.57 P/E if the $2.09 EPS is correct. After having $2.10 EPS previously, Canadian Imperial Bank of Commerce (USA)’s analysts see -0.48% EPS growth. The stock decreased 0.50% or $0.44 during the last trading session, reaching $88.4. About shares traded. Canadian Imperial Bank of Commerce (USA) (NYSE:CM) has risen 2.52% since November 15, 2016 and is uptrending. It has underperformed by 14.18% the S&P500.

Kura Oncology Incorporated (NASDAQ:KURA) had an increase of 36.6% in short interest. KURA’s SI was 2.00 million shares in November as released by FINRA. Its up 36.6% from 1.47M shares previously. With 423,800 avg volume, 5 days are for Kura Oncology Incorporated (NASDAQ:KURA)’s short sellers to cover KURA’s short positions. The SI to Kura Oncology Incorporated’s float is 18.39%. The stock decreased 5.33% or $0.85 during the last trading session, reaching $15.1. About shares traded. Kura Oncology Inc (NASDAQ:KURA) has risen 198.39% since November 15, 2016 and is uptrending. It has outperformed by 181.69% the S&P500.

Among 14 analysts covering Canadian Imperial Bank Of Commerce (NYSE:CM), 4 have Buy rating, 2 Sell and 8 Hold. Therefore 29% are positive. Canadian Imperial Bank Of Commerce had 27 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of Canadian Imperial Bank of Commerce (USA) (NYSE:CM) has “Hold” rating given on Monday, September 21 by Zacks. The company was maintained on Friday, December 4 by Macquarie Research. Bank of America initiated the stock with “Underperform” rating in Tuesday, November 1 report. The stock has “Outperform” rating by BMO Capital Markets on Monday, August 31. The rating was downgraded by Credit Agricole on Monday, December 7 to “Underperform”. As per Friday, February 24, the company rating was upgraded by Keefe Bruyette & Woods. The firm has “Market Perform” rating by BMO Capital Markets given on Friday, August 26. RBC Capital Markets maintained it with “Sector Perform” rating and $104 target in Thursday, June 30 report. Canaccord Genuity maintained the shares of CM in report on Thursday, August 27 with “Hold” rating. The rating was upgraded by Credit Suisse to “Underperform” on Thursday, August 27.

Canadian Imperial Bank of Commerce is a global financial institution. The company has market cap of $38.83 billion. The Firm provides a range of financial services and products to approximately 11 million individual, small business, commercial, corporate and institutional clients in Canada and around the world. It has a 10.23 P/E ratio. The Firm operates through three divisions: Retail and Business Banking, Wealth Management and Capital Markets.

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $418.09 million. The Firm is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. It currently has negative earnings. The Company’s segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Among 3 analysts covering Kura Oncology (NASDAQ:KURA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Kura Oncology had 4 analyst reports since December 16, 2015 according to SRatingsIntel. On Wednesday, December 30 the stock rating was initiated by Oppenheimer with “Outperform”. JMP Securities initiated the shares of KURA in report on Friday, January 22 with “Market Outperform” rating. As per Wednesday, December 16, the company rating was initiated by Citigroup. The firm earned “Outperform” rating on Thursday, February 11 by Oppenheimer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com